Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

Bhagirathbhai Dholaria; Aleksandar Radujkovic; Noel Estrada-Merly; Tiarlan Sirait; Soyoung Kim; Juan Carlos Hernández-Boluda; Tomasz Czerw; Patrick J. Hayden; Ankit Kansagra; Vincent T. Ho; Taiga Nishihori; Paul Shaughnessy; Bart Scott; Ryotaro Nakamura; Betul Oran; Mohamed Kharfan-Dabaja; Bipin N. Savani; Donal McLornan; Ibrahim Yakoub-Agha; Wael Saber

doi:10.1111/bjh.18297

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

Bhagirathbhai Dholaria, Aleksandar Radujkovic, Noel Estrada-Merly, Tiarlan Sirait, Soyoung Kim, Juan Carlos Hernández-Boluda, Tomasz Czerw, Patrick J. Hayden, Ankit Kansagra, Vincent T. Ho, Taiga Nishihori, Paul Shaughnessy, Bart Scott, Ryotaro Nakamura, Betul Oran, Mohamed Kharfan-Dabaja, Bipin N. Savani, Donal McLornan, Ibrahim Yakoub-Agha, Wael Saber

Stem Cell Transplantation

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	785-789
Number of pages	5
Journal	British Journal of Haematology
Volume	198
Issue number	4
DOIs	https://doi.org/10.1111/bjh.18297
State	Published - Aug 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.18297

Cite this

Dholaria, B., Radujkovic, A., Estrada-Merly, N., Sirait, T., Kim, S., Hernández-Boluda, J. C., Czerw, T., Hayden, P. J., Kansagra, A., Ho, V. T., Nishihori, T., Shaughnessy, P., Scott, B., Nakamura, R., Oran, B., Kharfan-Dabaja, M., Savani, B. N., McLornan, D., Yakoub-Agha, I., & Saber, W. (2022). Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. British Journal of Haematology, 198(4), 785-789. https://doi.org/10.1111/bjh.18297

Dholaria, B, Radujkovic, A, Estrada-Merly, N, Sirait, T, Kim, S, Hernández-Boluda, JC, Czerw, T, Hayden, PJ, Kansagra, A, Ho, VT, Nishihori, T, Shaughnessy, P, Scott, B, Nakamura, R, Oran, B, Kharfan-Dabaja, M, Savani, BN, McLornan, D, Yakoub-Agha, I & Saber, W 2022, 'Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis', British Journal of Haematology, vol. 198, no. 4, pp. 785-789. https://doi.org/10.1111/bjh.18297

@article{781fc1e88e4d43658745ff8a75da71f9,

title = "Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis",

author = "Bhagirathbhai Dholaria and Aleksandar Radujkovic and Noel Estrada-Merly and Tiarlan Sirait and Soyoung Kim and Hern{\'a}ndez-Boluda, {Juan Carlos} and Tomasz Czerw and Hayden, {Patrick J.} and Ankit Kansagra and Ho, {Vincent T.} and Taiga Nishihori and Paul Shaughnessy and Bart Scott and Ryotaro Nakamura and Betul Oran and Mohamed Kharfan-Dabaja and Savani, {Bipin N.} and Donal McLornan and Ibrahim Yakoub-Agha and Wael Saber",

note = "Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Institutes of Health National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases. It is also supported by the Health Resources and Services Administration (HHSH250201700006C and HHSH250201700007C) and the Office of Naval Research (N00014‐20‐1‐2705 and N00014‐20‐1‐2832). Additional federal support is provided by the National Institutes of Health National Cancer Institute (R01CA215134), the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI128775, U01AI126612), the National Institutes of Health National Heart, Lung, and Blood Institute (R01HL130388), the National Institutes of Health National Eye Institute (UG1HL06924), and the Biomedical Advanced Research and Development Authority. Support is also provided by Be the Match Foundation, Boston Children's Hospital, Dana Farber, St. Baldrick's Foundation, Stanford University, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: Actinium Pharmaceuticals, Inc., Adienne SA, AlloVir, Inc., Amgen, Inc., Angiocrine Bioscience, Astellas Pharma US, Bluebird Bio, Inc., Bristol Myers Squibb Co., Celgene Corp., CSL Behring, CytoSen Therapeutics, Inc., Daiichi Sankyo Co., Ltd., ExCellThera, Fate Therapeutics, Gamida Cell, Ltd., Genentech Inc., Incyte Corporation, Janssen/Johnson & Johnson, Jazz Pharmaceuticals, Inc., Kiadis Pharma, Kite, a Gilead Company, Kyowa Kirin, Legend Biotech, Magenta Therapeutics, Merck Sharp & Dohme Corp., Millennium, the Takeda Oncology Co., Miltenyi Biotec, Inc., Novartis Pharmaceuticals Corporation, Omeros Corporation, OncoImmune, Inc., Orca Biosystems, Inc., Pfizer, Inc., Pharmacyclics, LLC, Sanofi Genzyme, StemCyte, Takeda Pharma, Vor Biopharma and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defence, the Health Resources and Services Administration, or any other agency of the US government. We thank all the European Society for Blood and Marrow Transplantation (EBMT) centres and national registries for contributing patients to this study (Supplementary Appendix material). We also thank the data managers for their excellent work and the patients who contributed their data. Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Institutes of Health National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases. It is also supported by the Health Resources and Services Administration (HHSH250201700006C and HHSH250201700007C) and the Office of Naval Research (N00014-20-1-2705 and N00014-20-1-2832). Additional federal support is provided by the National Institutes of Health National Cancer Institute (R01CA215134), the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI128775, U01AI126612), the National Institutes of Health National Heart, Lung, and Blood Institute (R01HL130388), the National Institutes of Health National Eye Institute (UG1HL06924), and the Biomedical Advanced Research and Development Authority. Support is also provided by Be the Match Foundation, Boston Children's Hospital, Dana Farber, St. Baldrick's Foundation, Stanford University, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: Actinium Pharmaceuticals, Inc., Adienne SA, AlloVir, Inc., Amgen, Inc., Angiocrine Bioscience, Astellas Pharma US, Bluebird Bio, Inc., Bristol Myers Squibb Co., Celgene Corp., CSL Behring, CytoSen Therapeutics, Inc., Daiichi Sankyo Co., Ltd., ExCellThera, Fate Therapeutics, Gamida Cell, Ltd., Genentech Inc., Incyte Corporation, Janssen/Johnson & Johnson, Jazz Pharmaceuticals, Inc., Kiadis Pharma, Kite, a Gilead Company, Kyowa Kirin, Legend Biotech, Magenta Therapeutics, Merck Sharp & Dohme Corp., Millennium, the Takeda Oncology Co., Miltenyi Biotec, Inc., Novartis Pharmaceuticals Corporation, Omeros Corporation, OncoImmune, Inc., Orca Biosystems, Inc., Pfizer, Inc., Pharmacyclics, LLC, Sanofi Genzyme, StemCyte, Takeda Pharma, Vor Biopharma and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defence, the Health Resources and Services Administration, or any other agency of the US government. We thank all the European Society for Blood and Marrow Transplantation (EBMT) centres and national registries for contributing patients to this study (Supplementary Appendix material). We also thank the data managers for their excellent work and the patients who contributed their data.",

year = "2022",

month = aug,

doi = "10.1111/bjh.18297",

language = "English (US)",

volume = "198",

pages = "785--789",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia

T2 - A combined CIBMTR/CMWP of EBMT analysis

AU - Dholaria, Bhagirathbhai

AU - Radujkovic, Aleksandar

AU - Estrada-Merly, Noel

AU - Sirait, Tiarlan

AU - Kim, Soyoung

AU - Hernández-Boluda, Juan Carlos

AU - Czerw, Tomasz

AU - Hayden, Patrick J.

AU - Kansagra, Ankit

AU - Ho, Vincent T.

AU - Nishihori, Taiga

AU - Shaughnessy, Paul

AU - Scott, Bart

AU - Nakamura, Ryotaro

AU - Oran, Betul

AU - Kharfan-Dabaja, Mohamed

AU - Savani, Bipin N.

AU - McLornan, Donal

AU - Yakoub-Agha, Ibrahim

AU - Saber, Wael

N1 - Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Institutes of Health National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases. It is also supported by the Health Resources and Services Administration (HHSH250201700006C and HHSH250201700007C) and the Office of Naval Research (N00014‐20‐1‐2705 and N00014‐20‐1‐2832). Additional federal support is provided by the National Institutes of Health National Cancer Institute (R01CA215134), the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI128775, U01AI126612), the National Institutes of Health National Heart, Lung, and Blood Institute (R01HL130388), the National Institutes of Health National Eye Institute (UG1HL06924), and the Biomedical Advanced Research and Development Authority. Support is also provided by Be the Match Foundation, Boston Children's Hospital, Dana Farber, St. Baldrick's Foundation, Stanford University, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: Actinium Pharmaceuticals, Inc., Adienne SA, AlloVir, Inc., Amgen, Inc., Angiocrine Bioscience, Astellas Pharma US, Bluebird Bio, Inc., Bristol Myers Squibb Co., Celgene Corp., CSL Behring, CytoSen Therapeutics, Inc., Daiichi Sankyo Co., Ltd., ExCellThera, Fate Therapeutics, Gamida Cell, Ltd., Genentech Inc., Incyte Corporation, Janssen/Johnson & Johnson, Jazz Pharmaceuticals, Inc., Kiadis Pharma, Kite, a Gilead Company, Kyowa Kirin, Legend Biotech, Magenta Therapeutics, Merck Sharp & Dohme Corp., Millennium, the Takeda Oncology Co., Miltenyi Biotec, Inc., Novartis Pharmaceuticals Corporation, Omeros Corporation, OncoImmune, Inc., Orca Biosystems, Inc., Pfizer, Inc., Pharmacyclics, LLC, Sanofi Genzyme, StemCyte, Takeda Pharma, Vor Biopharma and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defence, the Health Resources and Services Administration, or any other agency of the US government. We thank all the European Society for Blood and Marrow Transplantation (EBMT) centres and national registries for contributing patients to this study (Supplementary Appendix material). We also thank the data managers for their excellent work and the patients who contributed their data. Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Institutes of Health National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases. It is also supported by the Health Resources and Services Administration (HHSH250201700006C and HHSH250201700007C) and the Office of Naval Research (N00014-20-1-2705 and N00014-20-1-2832). Additional federal support is provided by the National Institutes of Health National Cancer Institute (R01CA215134), the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI128775, U01AI126612), the National Institutes of Health National Heart, Lung, and Blood Institute (R01HL130388), the National Institutes of Health National Eye Institute (UG1HL06924), and the Biomedical Advanced Research and Development Authority. Support is also provided by Be the Match Foundation, Boston Children's Hospital, Dana Farber, St. Baldrick's Foundation, Stanford University, the Medical College of Wisconsin, the National Marrow Donor Program, and the following commercial entities: Actinium Pharmaceuticals, Inc., Adienne SA, AlloVir, Inc., Amgen, Inc., Angiocrine Bioscience, Astellas Pharma US, Bluebird Bio, Inc., Bristol Myers Squibb Co., Celgene Corp., CSL Behring, CytoSen Therapeutics, Inc., Daiichi Sankyo Co., Ltd., ExCellThera, Fate Therapeutics, Gamida Cell, Ltd., Genentech Inc., Incyte Corporation, Janssen/Johnson & Johnson, Jazz Pharmaceuticals, Inc., Kiadis Pharma, Kite, a Gilead Company, Kyowa Kirin, Legend Biotech, Magenta Therapeutics, Merck Sharp & Dohme Corp., Millennium, the Takeda Oncology Co., Miltenyi Biotec, Inc., Novartis Pharmaceuticals Corporation, Omeros Corporation, OncoImmune, Inc., Orca Biosystems, Inc., Pfizer, Inc., Pharmacyclics, LLC, Sanofi Genzyme, StemCyte, Takeda Pharma, Vor Biopharma and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defence, the Health Resources and Services Administration, or any other agency of the US government. We thank all the European Society for Blood and Marrow Transplantation (EBMT) centres and national registries for contributing patients to this study (Supplementary Appendix material). We also thank the data managers for their excellent work and the patients who contributed their data.

PY - 2022/8

Y1 - 2022/8

UR - http://www.scopus.com/inward/record.url?scp=85131178650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131178650&partnerID=8YFLogxK

U2 - 10.1111/bjh.18297

DO - 10.1111/bjh.18297

M3 - Letter

C2 - 35658101

AN - SCOPUS:85131178650

SN - 0007-1048

VL - 198

SP - 785

EP - 789

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this